Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $2.46 and last traded at $2.4150, with a volume of 444143 shares. The stock had previously closed at $2.29.
Analysts Set New Price Targets
Several brokerages have recently weighed in on AUTL. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and an average target price of $10.00.
Read Our Latest Stock Analysis on AUTL
Autolus Therapeutics Stock Performance
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. On average, research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.8 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after purchasing an additional 8,309 shares during the last quarter. Independent Advisor Alliance acquired a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $28,000. Marex Group plc acquired a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at $28,000. Waverly Advisors LLC purchased a new stake in Autolus Therapeutics during the 1st quarter worth about $37,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $43,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Featured Stories
- Five stocks we like better than Autolus Therapeutics
- The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
- Tesla’s Cybercab Launch Could Reshape Margins for Uber and Lyft
- Pony AI Stock Gains Traction as Robotaxi Fleet Expands Globally
- Amazon Plugs $18B Into the Southern Power Grid
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
